Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world- class manufacturing facilities in India, US and Canada and a team of...
The Company is engaged in the business of manufacturing Engines (Automotive applications, industrial applications, Auxiliary Power applications, Farm applications), Infrastructure Equipment (Road making, Concreting) and other products traded (Light agricultural equipment, Traded construction equipment and other adjacent products). GCL topline has witnessed a CAGR of 13% over the period FY03-FY13 and an impressive PAT CAGR of 53 percent over the same period. FY13 revenue stood at Rs. 1,873...
RPG Life Sciences Ltd. is an integrated Pharmaceutical Company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation API's space. The Company is a research based Pharmaceutical Company, producing a wide range of quality, affordable medicines and exports to Europe, Latin America, Canada and South East Asian Countries. In Q1FY14, the Company's turnover witnessed yoy growth of 15 percent to touch...
Sintex is engaged in manufacturing of textiles and plastic products. It also provides building solutions, auto components, civil construction (monolithic concrete construction) and EPC. SIL is looking forward to a growth of more than 30 percent in prefabricated business, while it expects the custom moulding business to grow due to improvement in the PMI index in US and Europe.In January-March quarter, Sintex had announced the acquisition of two bankrupt assets that are engaged in custom moulding in Germany and Poland at a consideration of Rs 170 crore....
Robust Q1FY14 performance: The Company reported a healthy performance which was evident in the form of 25.3% growth in standalone profit after tax to Rs. 22.74 bn in Q1-2014 on account of healthy growth of 12.6% on yoy basis in Retail loan book which forms 36% of the total Loan Book. On a consolidated basis too, PAT witnessed yoy growth of 32.3 percent to touch Rs. 27.47 bn in Q1FY14. Net interest income too increased by 19.6% on yoy basis; net interest margin...
BUY |Target Price: Rs. 245 | Upside: 34% Investment Summary Ajcon's view At CMP, the stock is available at attractive valuation of P/BV: 0.49x (FY13 Book value) which we feel is undervalued considering Bank's good performance in all fronts despite stressful economic conditions and peer PSU banks reporting dismal numbers with higher P/BV ratio. The bank scrip tanked 4.55 percent to Rs 183.50 on announcement of Q1FY14 result on the BSE, whose 30-share benchmark Sensex ended the session with 0.29 percent losses. The bank is not affected much on the liquidity and the costs front as a result of the recent RBI moves to tighten liquidity, conceding that treasury operations can face some...
We believe HDFC Bank is at an inception point where in the best performance of the bank is yet to be witnessed. In addition, we are of the view that it is one of the unique bank in the Indian Banking industry and will become one of the giants similar to SBI. Going back to value investing basics and replicating...
India's second biggest Company - RIL by market capitalization posted Revenues which were down by 4.6 percent to ` 90,589 crore on back of lower output from RIL's flagship KG-D6 gas fields and lower volume at the world's largest refining complex, which operated at 110 % capacity. GRM was at US$8.4 bbl versus US$8.5 in the previous quarter. Street had predicted profit to go up by 17-20% given the low base last year. Petrochemicals (petchem) earnings reduced due to the lack of improvement in oil and gas sector. As a result, we are slightly bearish on petchem segment. The management is optimistic about the petrochemicals business, where it is expanding capacity as it is investing heavily in the petchem business. RIL's new capacities are expected to start operations slowly and steadily from possibly H2FY14 onwards....
The market is going to keenly watch key earnings expected today. Strong April-June quarter numbers of TCS may also be a market game changer. On Thursday, equity benchmarks gained strength in late trade with the BSE Sensex gaining 180 points to close at 20128.41 on short covering in banks, capital goods and oil & gas stocks. Globally, the Dow and the S&P; 500 closed at record highs on Thursday after Morgan Stanley and others reported better-than-expected earnings and Federal Reserve Chairman Ben Bernanke's comments further reassured markets. The S&P; financial index climbed 1.3 percent. Of the 21 financial companies that have reported quarterly earnings so far, 76 percent have surpassed analysts' estimates, Thomson Reuters data showed. Both the Dow and the S&P; 500 also hit all-time intraday highs shortly after the opening bell. The Dow climbed as high as 15,589.40, while the S&P; 500 set a record session high of 1,693.12. Bernanke, speaking before the Senate Banking Committee, reiterated comments he...
IndusInd Bank posted Q1FY14 numbers above analyst expectations. Net Profit registered 42 percent yearon-year growth to touch Rs. 335 crore (as compared to street expectation of 34 percent growth in bottom line. Strong growth in other income helped by treasury gains and net interest income (NII) helped the Bank to post robust performance. NII was seen going up by 41 percent to Rs. 682 crore in the first quarter. During the quarter, other income surged 48 percent y-o-y to Rs. 471 crore while NII increased 40 percent to Rs 680 crore. Other income has increased owing to significant gains in treasury income. The Bank's treasury income has witnessed qoq growth of whopping 486 percent to touch Rs. 104.5 crores. Foreign exchange income also witnessed qoq growth of 26 percent to Rs. 92 crores in Q1FY14.The bank expanded its loan book by 27 percent to Rs. 47,425 crore. The recent promotional campaign of the Bank...
